FindTrial
Sign In

The association between tumor necrosis factor superfamily member 4 polymorphism and inflammatory bowel disease

TLR5, HLA-DOB, SERPINE1, IL12RB1, IL-7R, miRNAs, TNFSF13B, Study Title: The impact of TNFSF4 gene polymorphisms on susceptibility to inflammatory bowel disease and clinical responses to ustekinumab and vedolizumab.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110522
Enrollment
Unknown
Registered
2025-10-15
Start date
2025-10-20
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

Normal control:None
Corohn's disease group:None
Ulcerative colitis group:None

Sponsors

The Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Confirmed IBD patients were collected from the Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University.According to the consensus of "Diagnosis and treatment of inflammatory bowel disease" formulated by Chinese Society of Gastroenterology, the diagnosis of IBD was established by clinical, laboratory, radiographic, digestive endoscopy and histopathological examination.During the same period, 532 healthy subjects were collected from the physical examination center of our hospital as the normal control group. 1. Age: 18-70 years old; 2. Willing to accept standardized treatment and sign a written informed consent form. 3. Have not participated in other clinical trial programs in the past 3 months. 4. Within 14 days before inclusion in this study, laboratory test results show that blood routine, liver function, kidney function, coagulation function, electrolytes, and electrocardiogram are all within normal reference values. 5. No severe or life-threatening diseases in other systems.

Exclusion criteria

Exclusion criteria: 1. Age 70 years; 2. Pregnancy; 3. Breastfeeding; 4. Hepatic or renal insufficiency (transaminase and creatinine values >= 2 times the normal reference value); 5. Severe drug allergy (history of severe drug allergic reactions, such as anaphylactic shock, systemic dermatitis, etc.); 6. Presence of other autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroiditis); 7. Presence of malignant tumors; 8. Coagulation dysfunction (PT, INR, APTT >= 1.5 times the normal reference value); 9. Severe cardiovascular or cerebrovascular diseases; 10. Poor patient compliance or presence of psychiatric disorders; 11. Incomplete case data.

Design outcomes

Primary

MeasureTime frame
The correlation between TNFSF4 gene polymorphism and inflammatory bowel disease in Chinese Han population;—

Countries

China

Contacts

Public ContactJiang Yi

The Second Affiliated Hospital of Wenzhou Medical University

wzjiangyi@yeah.net+86 136 7671 5542

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026